BalazsHalmosMD

Oncology • Bronx, NY

Hematologic Oncology, Thoracic Cancer

Professor of Clinical Medicine Albert Einstein College of Medicine/ Montefiore Medical Center

Join to view full profile

Dr. Halmos is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Halmos' full profile

Already have an account?

Office
1695 Eastchester Rd
Bronx, NY 10461
Phone+1 718-405-8404

Fax+1 718-405-8433

Education & Training

Beth Israel Deaconess Medical CenterFellowship, Hematology and Medical Oncology, 1998 - 2001
Icahn School of Medicine at Mount Sinai/Morningside/WestResidency, Internal Medicine, 1995 - 1998
Semmelweis UniversityClass of 1992

Certifications & Licensure

NY State Medical License 2009 - 2026
OH State Medical License 2004 - 2010
MA State Medical License 2000 - 2004

Awards, Honors, & Recognition

Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012

Clinical Trials

Identifying Early Lung Cancer Cells in Malignant Pleural Effusion Samples From Patients With Primary Lung Cancer Start of enrollment: 2007 Jun 01
Withdrawn
Lapatinib Resistance in Patients With Breast Cancer Start of enrollment: 2008 Jul 01
Withdrawn
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer Start of enrollment: 2011 Feb 14
Completed
Phase 3
Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer Start of enrollment: 2011 Jan 11
Terminated
Phase 3
A Study of DKN-01 in Combination With Paclitaxel or Pembrolizumab Start of enrollment: 2014 May 05
Completed
Phase 1
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Jul 08
Completed
A Study of Abemaciclib (LY2835219) in Participants With Stage IV Squamous Non-small Cell Lung Cancer Start of enrollment: 2015 Aug 06
Completed
Phase 2
Necitumumab in the Neoadjuvant Setting With Gemcitabine in Surgically Resectable - 14X-US-I001 Start of enrollment: 2018 May 29
Terminated
Phase 2
Booster Dose Trial Start of enrollment: 2021 Aug 10
Recruiting
Phase 2
Roles: Contact
Phase 1/2 Study of BDTX-1535 in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations Start of enrollment: 2022 Mar 31
Recruiting
Phase 1, Phase 2
Roles: Contact
A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors Start of enrollment: 2020 Aug 19
Terminated
Phase 1, Phase 2
Roles: Contact
Apricity CARE to Improve ICI Outcomes of Ethnic/Racial Minority NSCLC Patients Start of enrollment: 2023 Apr 01
Not yet recruiting
Not Applicable
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

Surgery for Patients With cT3/4N2M0, Stage IIIB NSCLC. Is It Time to Redefine Resectability?
J Humberto Rodriguez-Quintero, Rajika Jindani, Roger Zhu, Isaac Loh, Mohamed K Kamel
JTO Clinical and Research Reports. 2025-01-01
Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2024.2.
Lyudmila Bazhenova, Nofisat Ismaila, Fawzi Abu Rous, Krishna Alluri, Janet Freeman-Daily
Journal of Clinical Oncology. 2024-12-20
Smoking carcinogen induced inflammation promotes lung carcinogenesis via IRAK4 activation.
Ritesh K Aggarwal, Simone Sidoli, Jingli Wang, Srabani Sahu, Rahul Sanawar
Clinical Cancer Research. 2024-12-20

Journal Articles

Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
Balazs Halmos, MD, The New England Journal of Medicine

Press Mentions

Stay Curious, Remain Humble: An Oncologist's Advice to His Younger SelfJuly 30th, 2024
I'm an Oncologist. New Yorkers Need Better Access to Biomarker Testing | OpinionMay 23rd, 2023
Four New York City Cancer Centers Receive $1 Million SU2C Grant to Improve Lung Cancer Care in Underserved Minority PatientsJune 27th, 2022
Join now to see all